|
1
|
Chi SW, Zang JB, Mele A and Darnell RB:
Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature.
460:479–486. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hale BJ, Yang CX and Ross JW: Small RNA
regulation of reproductive function. Mol Reprod Dev. 81:148–159.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: MiRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding J, Huang S, Wu S, Zhao Y, Liang L,
Yan M, Ge C, Yao J, Chen T, Wan D, et al: Gain of miR-151 on
chromosome 8q24.3 facilitates tumour cell migration and spreading
through downregulating RhoGDIA. Nat Cell Biol. 12:390–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kota J, Chivukula RR, O'Donnell KA,
Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P,
Torbenson M, Clark KR, et al: Therapeutic microRNA delivery
suppresses tumorigenesis in a murine liver cancer model. Cell.
137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang J, Gusev Y, Aderca I, Mettler TA,
Nagorney DM, Brackett DJ, Roberts LR and Schmittgen TD: Association
of MicroRNA expression in hepatocellular carcinomas with hepatitis
infection, cirrhosis, and patient survival. Clin Cancer Res.
14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gramantieri L, Ferracin M, Fornari F,
Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E,
Grazi GL, et al: Cyclin G1 is a target of miR-122a, a microRNA
frequently down-regulated in human hepatocellular carcinoma. Cancer
Res. 67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang YS, Dai Y, Yu XF, Bao SY, Yin YB,
Tang M and Hu CX: Microarray analysis of microRNA expression in
hepatocellular carcinoma and non-tumorous tissues without viral
hepatitis. J Gastroenterol Hepatol. 23:87–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Budhu A, Jia HL, Forgues M, Liu CG,
Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al:
Identification of metastasis-related microRNAs in hepatocellular
carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varnholt H, Drebber U, Schulze F,
Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene
expression profile of hepatitis C virus-associated hepatocellular
carcinoma. Hepatology. 47:1223–1232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar V, Fausto N and Abbas A: Robbins
& Cotran Pathologic Basis of Disease. 9th edition. Saunders;
Philadelphia, PA: pp. 870–873. 2015
|
|
17
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hao K, Luk JM, Lee NP, Mao M, Zhang C,
Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC and Poon RT: Predicting
prognosis in hepatocellular carcinoma after curative surgery with
common clinicopathologic parameters. BMC Cancer. 9:3892009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Connolly E, Melegari M, Landgraf P,
Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M,
Tuschl T and Rogler CE: Elevated expression of the miR-17-92
polycistron and miR-21 in hepadnavirus-associated hepatocellular
carcinoma contributes to the malignant phenotype. Am J Pathol.
173:856–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang F, Li QJ, Gong ZB, Zhou L, You N,
Wang S, Li XL, Li JJ, An JZ, Wang DS, et al: MicroRNA-34a targets
Bcl-2 and sensitizes human hepatocellular carcinoma cells to
sorafenib treatment. Technol Cancer Res Treat. 13:77–86. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dang Y, Luo D, Rong M and Chen G:
Underexpression of miR-34a in hepatocellular carcinoma and its
contribution towards enhancement of proliferating inhibitory
effects of agents targeting c-MET. PLoS One. 8:e610542013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang
Y, Jiang JD, Sung JJ, Cheng CH and Chen Y: A small-molecule
modulator of the tumor-suppressor miR34a inhibits the growth of
hepatocellular carcinoma. Cancer Res. 74:6236–6247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa
M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M and
Moriyama M: MicroRNA-375 is downregulated in gastric carcinomas and
regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer
Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X,
Cheng X, Lu W and Xie X: MiR-375 is upregulated in acquired
paclitaxel resistance in cervical cancer. Br J Cancer. 109:92–99.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan JW, Lin JS and He XX: The emerging
role of miR-375 in cancer. Int J Cancer. 135:1011–1018. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou N, Qu Y, Xu C and Tang Y:
Upregulation of microRNA-375 increases the cisplatin-sensitivity of
human gastric cancer cells by regulating ERBB2. Exp Ther Med.
11:625–630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du Y, Zhu M, Zhou X, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W and Wang T: MiR-20a enhances cisplatin
resistance of human gastric cancer cell line by targeting NFKBIB.
Tumour Biol. 37:1261–1269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Ahiekpor A, Li L, Li X, Arbuthnot
P, Kew M and Feitelson MA: Increased expression of ErbB-2 in liver
is associated with hepatitis B × antigen and shorter survival in
patients with liver cancer. Int J Cancer. 125:1894–1901. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun K and Lai EC: Adult-specific functions
of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Poy MN, Eliasson L, Krutzfeldt J, Kuwajima
S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P
and Stoffel M: A pancreatic islet-specific microRNA regulates
insulin secretion. Nature. 432:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Avnit-Sagi T, Kantorovich L, Kredo-Russo
S, Hornstein E and Walker MD: The promoter of the pri-miR-375 gene
directs expression selectively to the endocrine pancreas. PLoS One.
4:e50332009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu AM, Poon RT and Luk JM: MicroRNA-375
targets Hippo-signaling effector YAP in liver cancer and inhibits
tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Poy MN, Hausser J, Trajkovski M, Braun M,
Collins S, Rorsman P, Zavolan M and Stoffel M: MiR-375 maintains
normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci
USA. 106:5813–5818. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kloosterman WP, Lagendijk AK, Ketting RF,
Moulton JD and Plasterk RH: Targeted inhibition of miRNA maturation
with morpholinos reveals a role for miR-375 in pancreatic islet
development. PLoS Biol. 5:e2032007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen ZY, Zhang ZZ, Liu H, Zhao EH and Cao
H: MiR-375 inhibits the proliferation of gastric cancer cells by
repressing ERBB2 expression. Exp Ther Med. 7:1757–1761. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang ZW, Men T, Feng RC, Li YC, Zhou D
and Teng CB: MiR-375 inhibits proliferation of mouse pancreatic
progenitor cells by targeting YAP1. Cell Physiol Biochem.
32:1808–1817. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mitri Z, Constantine T and O'Regan R: The
HER2 receptor in breast cancer: Pathophysiology, clinical use, and
new advances in therapy. Chemother Res Pract.
2012:7431932012.PubMed/NCBI
|
